UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~May~~December 2025

Commission File Number: 001-42450

Zhengye Biotechnology Holding Limited

No.1 Lianmeng Road, Jilin Economic & Technical Development Zone

Jilin City, Jilin Province, China (Address of principal executive office)

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

~~Press~~Explanatory ~~Release Announcing Receipt of the NASDAQ Delinquency Notice~~Note

~~On May 20, 2025,~~ Zhengye Biotechnology Holding Limited, a Cayman Islands exempted company (the “Company”), ~~received~~is afurnishing ~~notice~~its ~~from~~unaudited ~~NASDAQ~~financial ~~Regulation~~statements ~~indicating~~and ~~that~~notes for the ~~Company~~six months ended isJune ~~not~~30, in2025. ~~compliance~~The ~~with~~financial ~~NASDAQ~~statements ~~Listing~~and ~~Rule~~notes ~~5250(c)(1)~~are ~~due~~attached as Exhibit 99.1 to ~~the~~this ~~Company~~report. Management’s ~~failure~~Discussion toand ~~timely~~Analysis of ~~file~~Financial ~~its~~Condition ~~Form~~and ~~20-F~~Results of Operations for the ~~fiscal year~~six months ended ~~December~~June 3130, ~~2024~~2025 byis ~~the~~attached ~~filing~~as ~~due~~Exhibit ~~date~~99.2 ofto ~~May~~this ~~15, 2025 (the “NASDAQ Delinquency Notice”)~~report.

On May 23, 2025, Zhengye Biotechnology Holding Limited issued a press release announcing receipt of the NASDAQ Delinquency Notice. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit Index

Exhibit No.		Description
99.1		~~Press~~Unaudited ~~Release~~Consolidated ~~titled~~Financial “Statements and Notes of Zhengye Biotechnology Holding Limited ~~Receives~~for ~~NASDAQ~~the ~~Notice~~Six ~~Related~~Months toEnded ~~Late~~June ~~Filing~~30, of2025 ~~Form~~and ~~20-F”~~2024
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations
101. INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Zhengye Biotechnology Holding Limited
Date: May 23, 2025	By:	/s/ Songlin Song
Date: December 12, 2025	By:	/s/ Songlin Song
	Name:	Songlin Song
	Title:	Chief Executive Officer

Filing Compare · Zhengye Biotechnology Holding Ltd